NCT04976634
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04976634 |
| Title | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS |
CKB BOOST